publication . Other literature type . Article . 2012

Short-term clinical outcomes for stages of NIA-AA preclinical Alzheimer disease.

Knopman, D. S.; Jack, C. R.; Wiste, H. J.; Weigand, S. D.; Vemuri, P.; Lowe, V.; Kantarci, K.; Gunter, J. L.; Senjem, M. L.; Ivnik, R. J.; ...
Open Access English
  • Published: 02 May 2012
  • Publisher: Lippincott Williams & Wilkins
Objective: Recommendations for the diagnosis of preclinical Alzheimer disease (AD) have been formulated by a workgroup of the National Institute on Aging and Alzheimer’s Association. Three stages of preclinical AD were described. Stage 1 is characterized by abnormal levels of β-amyloid. Stage 2 represents abnormal levels of β-amyloid and evidence of brain neurodegeneration. Stage 3 includes the features of stage 2 plus subtle cognitive changes. Stage 0, not explicitly defined in the criteria, represents subjects with normal biomarkers and normal cognition. The ability of the recommended criteria to predict progression to cognitive impairment is the crux of their...
Medical Subject Headings: mental disorders
free text keywords: Articles, Clinical Neurology, Internal medicine, medicine.medical_specialty, medicine, Oncology, Diabetes mellitus, medicine.disease, Dementia, Pittsburgh compound B, chemistry.chemical_compound, chemistry, Chi-squared distribution, Pathology, Physical therapy, Biomarker (medicine), Fluorodeoxyglucose, medicine.drug, business.industry, business, Alzheimer's disease, Cognitive test
Download fromView all 3 versions
Europe PubMed Central
Other literature type . 2012
Provider: UnpayWall
Other literature type . 2012
Provider: Datacite
Powered by OpenAIRE Research Graph
Any information missing or wrong?Report an Issue